• Profile
Close

Accelerated step-up infliximab use is associated with sustained primary response in pediatric Crohn's disease

Digestive Diseases and Sciences Mar 21, 2018

Ling J, et al. - Authors sought to analyze the correlation between the time of introduction of infliximab (IFX) in Crohn’s disease (CD) with a sustained remission. Yielded data demonstrated that the early step-up use of IFX in children with CD with inadequate clinical response to conventional therapies gave rise to sustained primary response over 2 years.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay